Pfizer is pursuing expanded use of its PARP inhibitor Talzenna in prostate cancer treatment based on new clinical data. The drug, acquired through a $14 billion deal, is being studied for use in earlier lines of prostate cancer care.
The new results come from studies examining Talzenna's effectiveness in earlier-stage prostate cancer patients, potentially expanding its current treatment applications. PARP inhibitors work by blocking DNA repair mechanisms in cancer cells, making them particularly effective in tumors with certain genetic characteristics.